NIS303.8m market cap
NIS1.89 last close
Clal Biotechnology Industries is a healthcare investment company focused on investing in a variety of therapeutic, diagnostic, and medical device companies covering a full range of development phases from preclinical to post-market.
Investment summary
Clal Biotechnology (CBI) is a healthcare investment company with an extensive portfolio incorporating a diverse range of technologies, indications and stages of development. CBI holds direct investments in 10 companies (nine biotech and one medical device company), most importantly MediWound, a NASDAQ-listed wound care company and Gamida Cell, which is developing a universal bone marrow transplant product and recently listed on the NASDAQ. Also, Anchiano and Biokine have programmes in Phase III or Phase III ready. The year 2019 proved to be eventful for CBI’s investments with MediWound announcing a successful Phase III study for NexoBrid as well as a license agreement for that product and Anchiano successfully listing on NASDAQ.
Y/E Dec |
Revenue (NISm) |
EBITDA (NISm) |
PBT (NISm) |
EPS (NIS) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 73.6 | (103.3) | (54.2) | (15.02) | N/A | N/A |
| 2018A | 85.3 | (54.0) | (40.9) | (18.21) | N/A | N/A |
| 2019E | N/A | N/A | N/A | N/A | N/A | N/A |
| 2020E | N/A | N/A | N/A | N/A | N/A | N/A |
Industry outlook
CBI is invested in a variety of life science companies, including a wide and diverse range of technologies, indications and stages of development, all of which have high potential.
Last updated on 26/02/2021
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (NISm) | N/A |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Ofer Gonen | CEO |
| Assaf Segal | CFO |
| Gilad Rosenberg | Medical Director |
| Ofer Goldberg | Vice President |
